Gouillat C
Department of Surgery Hôtel Dieu, Lyon, France.
Digestion. 1999;60 Suppl 3:59-63. doi: 10.1159/000051490.
Pancreatoduodenectomy (PD) may be followed by serious complications chiefly associated with exocrine pancreatic secretion. Somatostatin and its analogues are able to inhibit pancreatic secretion and thus have been advocated for the prevention of complications following pancreatic surgery. In four published multicentric randomized trials, octreotide administration was associated with a decrease in overall complication rate. However and surprisingly, the benefit is less clear when focusing on complications associated with pancreatic secretion as in pancreatic fistula or in high-risk patients (PD and nonfibrotic pancreas). The efficiency of other somatostatin analogues has not yet been assessed in randomized trials. In conclusion, further studies would be useful before routine prophylactic administration of somatostatin analogues can be recommended.
胰十二指肠切除术（PD）术后可能会出现主要与胰腺外分泌相关的严重并发症。生长抑素及其类似物能够抑制胰腺分泌，因此一直被提倡用于预防胰腺手术后的并发症。在四项已发表的多中心随机试验中，使用奥曲肽与总体并发症发生率的降低相关。然而，令人惊讶的是，当关注与胰腺分泌相关的并发症时，如胰瘘或高危患者（PD和非纤维化胰腺），其益处并不那么明显。其他生长抑素类似物的疗效尚未在随机试验中得到评估。总之，在推荐常规预防性使用生长抑素类似物之前，进一步的研究将是有益的。
